215 related articles for article (PubMed ID: 31670653)
1. Persistence and adherence to dutasteride/tamsulosin fixed-dose versus free-combination alpha blocker/5ARI therapy in patients with benign prostate hyperplasia in Germany
.
Eisen C; Lulic Z; Palacios-Moreno JM; Adalig B; Hennig M; Cortes V; Gilg F; Kostev K
Int J Clin Pharmacol Ther; 2020 Jan; 58(1):37-49. PubMed ID: 31670653
[TBL] [Abstract][Full Text] [Related]
2. A prospective randomised placebo-controlled study of the impact of dutasteride/tamsulosin combination therapy on sexual function domains in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).
Roehrborn CG; Manyak MJ; Palacios-Moreno JM; Wilson TH; Roos EPM; Santos JC; Karanastasis D; Plastino J; Giuliano F; Rosen RC
BJU Int; 2018 Apr; 121(4):647-658. PubMed ID: 29044968
[TBL] [Abstract][Full Text] [Related]
3. Dutasteride plus tamsulosin fixed-dose combination first-line therapy versus tamsulosin monotherapy in the treatment of benign prostatic hyperplasia: a budget impact analysis in the Greek healthcare setting.
Geitona M; Karabela P; Katsoulis IA; Kousoulakou H; Lyberopoulou E; Bitros E; Xaplanteris L; Papanicolaou S
BMC Urol; 2014 Sep; 14():78. PubMed ID: 25255740
[TBL] [Abstract][Full Text] [Related]
4. A retrospective study of treatment persistence and adherence to α-blocker plus antimuscarinic combination therapies, in men with LUTS/BPH in the Netherlands.
Drake MJ; Bowditch S; Arbe E; Hakimi Z; Guelfucci F; Amri I; Nazir J
BMC Urol; 2017 May; 17(1):36. PubMed ID: 28532455
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the impact of dutasteride/tamsulosin combination therapy on libido in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH): A post hoc analysis of a prospective randomised placebo-controlled study.
Rosen RC; Roehrborn CG; Manyak MJ; Palacios-Moreno JM; Wilson TH; Lulic Z; Giuliano F
Int J Clin Pract; 2019 Sep; 73(9):1-9. PubMed ID: 30317693
[TBL] [Abstract][Full Text] [Related]
6. Early symptom improvement and discontinuation of 5-α-reductase inhibitor (5ARI) therapy in patients with benign prostatic hyperplasia (BPH).
Kruep EJ; Phillips E; Hogue S; Eaddy M
Ann Pharmacother; 2014 Mar; 48(3):343-8. PubMed ID: 24311727
[TBL] [Abstract][Full Text] [Related]
7. Men's Sexual Health Questionnaire score changes vs spontaneous sexual adverse event reporting in men treated with dutasteride/tamsulosin combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A post hoc analysis of a prospective, randomised, placebo-controlled study.
Roehrborn CG; Rosen RC; Manyak MJ; Palacios-Moreno JM; Wilson TH; Lulic Z; Giuliano F
Int J Clin Pract; 2020 May; 74(5):e13480. PubMed ID: 31927774
[TBL] [Abstract][Full Text] [Related]
8. [Cost-effectiveness of the combination therapy of dutasteride and tamsulosin in the treatment of benign prostatic hyperlasia in Spain].
Antoñanzas F; Brenes F; Molero JM; Fernández-Pro A; Huerta A; Palencia R; Cozar JM
Actas Urol Esp; 2011 Feb; 35(2):65-71. PubMed ID: 21269736
[TBL] [Abstract][Full Text] [Related]
9. Comparing Clinical and Economic Outcomes Associated with Early Initiation of Combination Therapy of an Alpha Blocker and Dutasteride or Finasteride in Men with Benign Prostatic Hyperplasia in the United States.
DerSarkissian M; Xiao Y; Duh MS; Lefebvre P; Swensen AR; Bell CF
J Manag Care Spec Pharm; 2016 Oct; 22(10):1204-14. PubMed ID: 27668569
[TBL] [Abstract][Full Text] [Related]
10. Treatment persistence with a fixed-dose combination of tadalafil (5 mg) and tamsulosin (0.4 mg) and reasons for early discontinuation in patients with benign prostatic hyperplasia and erectile dysfunction.
Ahn ST; Lee DH; Jeong HG; Kim JW; Oh MM; Park HS; Moon DG
Investig Clin Urol; 2020 Jan; 61(1):81-87. PubMed ID: 31942467
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of combination therapy with tamsulosin, dutasteride and imidafenacin for the management of overactive bladder symptoms associated with benign prostatic hyperplasia: A multicenter, randomized, open-label, controlled trial (DIrecT Study).
Yamanishi T; Asakura H; Seki N; Tokunaga S
Int J Urol; 2017 Jul; 24(7):525-531. PubMed ID: 28466585
[TBL] [Abstract][Full Text] [Related]
12. Quality of life in patients with lower urinary tract symptoms associated with BPH: change over time in real-life practice according to treatment--the QUALIPROST study.
Alcaraz A; Carballido-Rodríguez J; Unda-Urzaiz M; Medina-López R; Ruiz-Cerdá JL; Rodríguez-Rubio F; García-Rojo D; Brenes-Bermúdez FJ; Cózar-Olmo JM; Baena-González V; Manasanch J
Int Urol Nephrol; 2016 May; 48(5):645-56. PubMed ID: 26810324
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
Roehrborn CG; Barkin J; Siami P; Tubaro A; Wilson TH; Morrill BB; Gagnier RP
BJU Int; 2011 Mar; 107(6):946-54. PubMed ID: 21332630
[TBL] [Abstract][Full Text] [Related]
14. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart(®) ) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naïve men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results.
Roehrborn CG; Oyarzabal Perez I; Roos EP; Calomfirescu N; Brotherton B; Wang F; Palacios JM; Vasylyev A; Manyak MJ
BJU Int; 2015 Sep; 116(3):450-9. PubMed ID: 25565364
[TBL] [Abstract][Full Text] [Related]
16. A retrospective analysis comparing persistence and adherence to treatment with free- vs fixed-dose combination of an alpha blocker and an antimuscarinic agent in men with LUTS in Spain.
Landeira M; Mora Blázquez AM; Martins de Almeida R; Covernton PJO; Medina-Polo J; Alcántara Montero A
Int J Clin Pract; 2020 Nov; 74(11):e13616. PubMed ID: 32681522
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes of withdrawing one medication from long-term combination therapy comprising α-blocker and 5α-reductase inhibitor for benign prostatic hyperplasia.
Choi JD; Yoo TK; Kang JY; Jung HD; Lee JH
Int Urol Nephrol; 2023 Apr; 55(4):845-851. PubMed ID: 36763223
[TBL] [Abstract][Full Text] [Related]
18. Free combination of dutasteride plus tamsulosin for the treatment of benign prostatic hyperplasia in South Korea: analysis of drug utilization and adverse events using the National Health Insurance Review and Assessment Service database.
Lulic Z; Son H; Yoo SB; Cunnington M; Kapse P; Miller D; Cortes V; Park S; Bhak RH; Duh MS
BMC Urol; 2021 Dec; 21(1):178. PubMed ID: 34933674
[TBL] [Abstract][Full Text] [Related]
19. Can we use baseline characteristics to assess which men with moderately symptomatic benign prostatic hyperplasia at risk of progression will benefit from treatment? A post hoc analysis of data from the 2-year CONDUCT study.
Roehrborn CG; Oyarzabal Perez I; Roos EP; Calomfirescu N; Brotherton B; Palacios JM; Vasylyev A; Manyak MJ
World J Urol; 2017 Mar; 35(3):421-427. PubMed ID: 27334136
[TBL] [Abstract][Full Text] [Related]
20. Association between
Madersbacher S; Rieken M; Reuber K; Kostev K
Postgrad Med; 2023 Mar; 135(2):149-154. PubMed ID: 36408978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
